TAE Life Sciences and The Ohio State University Comprehensive Cancer Center have announced a landmark collaboration focused on advancing boron-based drug innovation for Boron Neutron Capture Therapy (BNCT), a precision cancer treatment. This first-of-its-kind U.S. academic-industry partnership aims to accelerate the development and evaluation of novel boron compounds, which are crucial for BNCT’s effectiveness in selectively targeting cancer cells while sparing healthy tissue.
The initial phase will involve preclinical evaluation of TAE Life Sciences’ proprietary boron-10 drugs using Ohio State’s specialized neutron source. Simultaneously, the teams will jointly develop next-generation boron drugs for BNCT and related applications in precision oncology.
Dr. Arnab Chakravarti of Ohio State emphasized BNCT’s potential for treating unresponsive malignancies with minimal toxicity, highlighting their institution’s readiness to lead boron drug innovation. Robert Hill, CEO of TAE Life Sciences, expressed honor in partnering with Ohio State’s experts, anticipating significant progress in novel boron drug development and regulatory pathways. He noted the collaboration’s importance in advancing accelerator-based BNCT and positioning the U.S. as a leader in precision oncology, building upon promising international clinical data. This alliance aims to redefine cancer care by unlocking BNCT’s full therapeutic potential.